1
|
Vogelgsang J, Hansen N, Stark M, Wagner M, Klafki H, Morgado BM, Jahn‐Brodmann A, Schott B, Esselmann H, Bauer C, Schuchhardt J, Kleineidam L, Wolfsgruber S, Peters O, Schneider L, Wang X, Menne F, Priller J, Spruth E, Altenstein S, Lohse A, Schneider A, Fliessbach K, Vogt I, Bartels C, Jessen F, Rostamzadeh A, Duezel E, Glanz W, Incesoy E, Butryn M, Buerger K, Janowitz D, Ewers M, Perneczky R, Rauchmann B, Guersel S, Teipel S, Kilimann I, Goerss D, Laske C, Munk M, Sanzenbacher C, Spottke A, Roy‐Kluth N, Heneka M, Brosseron F, Ramierez A, Schmid M, Wiltfang J. Plasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer's disease. Alzheimers Dement 2024; 20:5132-5142. [PMID: 38940303 PMCID: PMC11350048 DOI: 10.1002/alz.13909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 03/30/2024] [Accepted: 04/02/2024] [Indexed: 06/29/2024]
Abstract
INTRODUCTION Blood-based biomarkers are a cost-effective and minimally invasive method for diagnosing the early and preclinical stages of amyloid positivity (AP). Our study aims to investigate our novel immunoprecipitation-immunoassay (IP-IA) as a test for predicting cognitive decline. METHODS We measured levels of amyloid beta (Aβ)X-40 and AβX-42 in immunoprecipitated eluates from the DELCODE cohort. Receiver-operating characteristic (ROC) curves, regression analyses, and Cox proportional hazard regression models were constructed to predict AP by Aβ42/40 classification in cerebrospinal fluid (CSF) and conversion to mild cognitive impairment (MCI) or dementia. RESULTS We detected a significant correlation between AßX-42/X-40 in plasma and CSF (r = 0.473). Mixed-modeling analysis revealed a substantial prediction of AßX-42/X-40 with an area under the curve (AUC) of 0.81 for AP (sensitivity: 0.79, specificity: 0.74, positive predictive value [PPV]: 0.71, negative predictive value [NPV]: 0.81). In addition, lower AβX-42/X-40 ratios were associated with negative PACC5 slopes, suggesting cognitive decline. DISCUSSION Our results suggest that assessing the plasma AβX-42/X-40 ratio via our semiautomated IP-IA is a promising biomarker when examining patients with early or preclinical AD. HIGHLIGHTS New plasma Aβ42/Aβ40 measurement using immunoprecipitation-immunoassay Plasma Aβ42/Aβ40 associated with longitudinal cognitive decline Promising biomarker to detect subjective cognitive decline at-risk for brain amyloid positivity.
Collapse
Affiliation(s)
- Jonathan Vogelgsang
- Department of PsychiatryMcLean Hospital, Harvard Medical SchoolBelmontMassachusettsUSA
| | - Niels Hansen
- Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
| | - Melina Stark
- German Center for Neurodegenerative Disorders (DZNE)BonnGermany
- Department of Neurodegenerative Diseases and Geriatric PsychiatryUniversity of Bonn Medical CenterBonnGermany
| | - Michael Wagner
- German Center for Neurodegenerative Disorders (DZNE)BonnGermany
- Department of Neurodegenerative Diseases and Geriatric PsychiatryUniversity of Bonn Medical CenterBonnGermany
| | - Hans Klafki
- Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
| | - Barbara Marcos Morgado
- Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
| | - Anke Jahn‐Brodmann
- Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
| | - Björn Schott
- Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
| | - Hermann Esselmann
- Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
| | | | | | - Luca Kleineidam
- German Center for Neurodegenerative Disorders (DZNE)BonnGermany
- Department of Neurodegenerative Diseases and Geriatric PsychiatryUniversity of Bonn Medical CenterBonnGermany
| | - Steffen Wolfsgruber
- German Center for Neurodegenerative Disorders (DZNE)BonnGermany
- Department of Neurodegenerative Diseases and Geriatric PsychiatryUniversity of Bonn Medical CenterBonnGermany
| | - Oliver Peters
- German Center for Neurodegenerative Diseases (DZNE)BerlinGermany
- Department of Psychiatry and PsychotherapyCharité – Universitätsmedizin BerlinBerlinGermany
| | - Luisa‐Sophie Schneider
- Department of Psychiatry and PsychotherapyCharité – Universitätsmedizin BerlinBerlinGermany
| | - Xiao Wang
- Department of Psychiatry and PsychotherapyCharité – Universitätsmedizin BerlinBerlinGermany
| | - Felix Menne
- German Center for Neurodegenerative Diseases (DZNE)BerlinGermany
- Predemtec AG, Rudower Chausee 29BerlinGermany
| | - Josef Priller
- German Center for Neurodegenerative Diseases (DZNE)BerlinGermany
- Department of Psychiatry and PsychotherapyCharité – Universitätsmedizin BerlinBerlinGermany
- School of MedicineDepartment of Psychiatry and PsychotherapyTechnical University of MunichMunichGermany
- University of Edinburgh and UK DRIEdinburghUK
| | - Eike Spruth
- German Center for Neurodegenerative Diseases (DZNE)BerlinGermany
- Department of Psychiatry and PsychotherapyCharité – Universitätsmedizin BerlinBerlinGermany
| | - Slawek Altenstein
- German Center for Neurodegenerative Diseases (DZNE)BerlinGermany
- Department of Psychiatry and PsychotherapyCharité – Universitätsmedizin BerlinBerlinGermany
| | - Andrea Lohse
- Department of Psychiatry and PsychotherapyCharité – Universitätsmedizin BerlinBerlinGermany
| | - Anja Schneider
- German Center for Neurodegenerative Disorders (DZNE)BonnGermany
- Department of Neurodegenerative Diseases and Geriatric PsychiatryUniversity of Bonn Medical CenterBonnGermany
| | - Klaus Fliessbach
- German Center for Neurodegenerative Disorders (DZNE)BonnGermany
- Department of Neurodegenerative Diseases and Geriatric PsychiatryUniversity of Bonn Medical CenterBonnGermany
| | - Ina Vogt
- German Center for Neurodegenerative Disorders (DZNE)BonnGermany
| | - Claudia Bartels
- Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
| | - Frank Jessen
- German Center for Neurodegenerative Disorders (DZNE)BonnGermany
- Department of PsychiatryUniversity of Cologne, Medical FacultyCologneGermany
- Excellence Cluster on Cellular Stress Response in Aging‐Associated Diseases (CECAD), University of CologneCologneGermany
| | - Ayda Rostamzadeh
- Department of PsychiatryUniversity of Cologne, Medical FacultyCologneGermany
| | - Emrah Duezel
- German Center for Neurodegenerative Diseases (DZNE)MagdeburgGermany
- Institute of Cognitive Neurology and Dementia Research (IKND)Otto‐von‐Guericke UniversityMagdeburgGermany
| | - Wenzel Glanz
- German Center for Neurodegenerative Diseases (DZNE)MagdeburgGermany
| | - Enise Incesoy
- German Center for Neurodegenerative Diseases (DZNE)MagdeburgGermany
- Institute of Cognitive Neurology and Dementia Research (IKND)Otto‐von‐Guericke UniversityMagdeburgGermany
- Department for Psychiatry and PsychotherapyUniversity Clinic MagdeburgMagdeburgGermany
| | - Michaela Butryn
- German Center for Neurodegenerative Diseases (DZNE)MagdeburgGermany
| | - Katharina Buerger
- German Center for Neurodegenerative Diseases (DZNE, Munich)MunichGermany
- Institute for Stroke and Dementia Research (ISD)University Hospital, LMU MunichMunichGermany
| | - Daniel Janowitz
- Institute for Stroke and Dementia Research (ISD)University Hospital, LMU MunichMunichGermany
| | - Michael Ewers
- German Center for Neurodegenerative Diseases (DZNE, Munich)MunichGermany
- Institute for Stroke and Dementia Research (ISD)University Hospital, LMU MunichMunichGermany
| | - Robert Perneczky
- German Center for Neurodegenerative Diseases (DZNE, Munich)MunichGermany
- Department of Psychiatry and PsychotherapyUniversity Hospital, LMU MunichMunichGermany
- Munich Cluster for Systems Neurology (SyNergy) MunichMunichGermany
- Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, South KensingtonLondonUK
| | - Boris Rauchmann
- Department of Psychiatry and PsychotherapyUniversity Hospital, LMU MunichMunichGermany
- Sheffield Institute for Translational Neuroscience (SITraN)University of Sheffield, BroomhallSheffieldUK
- Department of NeuroradiologyUniversity Hospital LMUMarchioninistrasseeMunichGermany
| | - Selim Guersel
- Department of Psychiatry and PsychotherapyUniversity Hospital, LMU MunichMunichGermany
| | - Stefan Teipel
- German Center for Neurodegenerative Diseases (DZNE)RostockGermany
- Department of Psychosomatic MedicineRostock University Medical CenterRostockGermany
| | - Ingo Kilimann
- German Center for Neurodegenerative Diseases (DZNE)RostockGermany
- Department of Psychosomatic MedicineRostock University Medical CenterRostockGermany
| | - Doreen Goerss
- German Center for Neurodegenerative Diseases (DZNE)RostockGermany
- Department of Psychosomatic MedicineRostock University Medical CenterRostockGermany
| | - Christoph Laske
- German Center for Neurodegenerative Diseases (DZNE)TuebingenGermany
- Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and PsychotherapyUniversity of TuebingenTuebingenGermany
| | - Matthias Munk
- German Center for Neurodegenerative Diseases (DZNE)TuebingenGermany
- Department of Psychiatry and PsychotherapyUniversity of TuebingenTuebingenGermany
| | | | - Annika Spottke
- German Center for Neurodegenerative Disorders (DZNE)BonnGermany
- Department of NeurologyUniversity of BonnBonnGermany
| | - Nina Roy‐Kluth
- German Center for Neurodegenerative Disorders (DZNE)BonnGermany
| | - Michael Heneka
- Luxembourg Centre for Systems Biomedicine (LCSB)University of LuxembourgEsch‐Belval Esch‐sur‐AlzetteLuxembourg
| | | | - Alfredo Ramierez
- German Center for Neurodegenerative Disorders (DZNE)BonnGermany
- Department of Neurodegenerative Diseases and Geriatric PsychiatryUniversity of Bonn Medical CenterBonnGermany
- Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases (CECAD)University of CologneCologneGermany
- Division of Neurogenetics and Molecular PsychiatryDepartment of Psychiatry and PsychotherapyFaculty of Medicine and University Hospital CologneUniversity of CologneCologneGermany
- Department of Psychiatry & Glenn Biggs Institute for Alzheimer's and Neurodegenerative DiseasesSan AntonioTexasUSA
| | - Matthias Schmid
- German Center for Neurodegenerative Disorders (DZNE)BonnGermany
- Institute for Medical BiometryUniversity Hospital BonnBonnGermany
| | - Jens Wiltfang
- Department of Psychiatry and PsychotherapyUniversity Medical Center GoettingenGoettingenGermany
- German Center for Neurodegenerative Diseases (DZNE)GoettingenGermany
- Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED)Department of Medical SciencesUniversity of AveiroAveiroPortugal
| |
Collapse
|
2
|
Bigler ED, Allder S, Victoroff J. What traditional neuropsychological assessment got wrong about mild traumatic brain injury. II: limitations in test development, research design, statistical and psychometric issues. Brain Inj 2024:1-22. [PMID: 39066740 DOI: 10.1080/02699052.2024.2376261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 05/16/2024] [Accepted: 06/30/2024] [Indexed: 07/30/2024]
Abstract
PRIMARY OBJECTIVE This is Part II of a four-part opinion review on traditional neuropsychological assessment methods and findings associated with mild traumatic brain injury (mTBI). This Part II review focuses on historical, psychometric and statistical issues involving traditional neuropsychological methods that have been used in neuropsychological outcome studies of mTBI, but demonstrates the critical limitations of traditional methods. RESEARCH DESIGN This is an opinion review. METHODS AND PROCEDURES Traditional neuropsychological tests are dated and lack specificity in evaluating such a heterogenous and complex injury as occurs with mTBI. MAIN OUTCOME AND RESULTS In this review, we demonstrate traditional neuropsychological methods were never developed as standalone measures for detecting subtle changes in neurocognitive or neurobehavioral functioning and likewise, never designed to address the multifaceted issues related to underlying mTBI neuropathology symptom burden from having sustained a concussive brain injury. CONCLUSIONS For neuropsychological assessment to continue to contribute to clinical practice and outcome literature involving mTBI, major innovative changes are needed that will likely require technological advances of novel assessment techniques more specifically directed to evaluating the mTBI patient. These will be discussed in Part IV.
Collapse
Affiliation(s)
- Erin D Bigler
- Department of Psychology and Neuroscience Center, Brigham Young University, Provo, Utah, USA
- Departments of Neurology and Psychiatry, University of Utah, Salt Lake City, Utah, USA
| | - Steven Allder
- Consultant Neurologist and Clinical Director, Re: Cognition Health, London, UK
| | - Jeff Victoroff
- Department of Neurology, University of Southern California, Los Angeles, California, USA
| |
Collapse
|
3
|
Berron D, Olsson E, Andersson F, Janelidze S, Tideman P, Düzel E, Palmqvist S, Stomrud E, Hansson O. Remote and unsupervised digital memory assessments can reliably detect cognitive impairment in Alzheimer's disease. Alzheimers Dement 2024; 20:4775-4791. [PMID: 38867417 PMCID: PMC11247711 DOI: 10.1002/alz.13919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Revised: 04/05/2024] [Accepted: 05/02/2024] [Indexed: 06/14/2024]
Abstract
INTRODUCTION Remote unsupervised cognitive assessments have the potential to complement and facilitate cognitive assessment in clinical and research settings. METHODS Here, we evaluate the usability, validity, and reliability of unsupervised remote memory assessments via mobile devices in individuals without dementia from the Swedish BioFINDER-2 study and explore their prognostic utility regarding future cognitive decline. RESULTS Usability was rated positively; remote memory assessments showed good construct validity with traditional neuropsychological assessments and were significantly associated with tau-positron emission tomography and downstream magnetic resonance imaging measures. Memory performance at baseline was associated with future cognitive decline and prediction of future cognitive decline was further improved by combining remote digital memory assessments with plasma p-tau217. Finally, retest reliability was moderate for a single assessment and good for an aggregate of two sessions. DISCUSSION Our results demonstrate that unsupervised digital memory assessments might be used for diagnosis and prognosis in Alzheimer's disease, potentially in combination with plasma biomarkers. HIGHLIGHTS Remote and unsupervised digital memory assessments are feasible in older adults and individuals in early stages of Alzheimer's disease. Digital memory assessments are associated with neuropsychological in-clinic assessments, tau-positron emission tomography and magnetic resonance imaging measures. Combination of digital memory assessments with plasma p-tau217 holds promise for prognosis of future cognitive decline. Future validation in further independent, larger, and more diverse cohorts is needed to inform clinical implementation.
Collapse
Affiliation(s)
- David Berron
- Clinical Memory Research Unit, Department of Clinical Sciences MalmöLund UniversityLundSweden
- German Center for Neurodegenerative DiseasesMagdeburgGermany
| | - Emil Olsson
- Clinical Memory Research Unit, Department of Clinical Sciences MalmöLund UniversityLundSweden
| | | | - Shorena Janelidze
- Clinical Memory Research Unit, Department of Clinical Sciences MalmöLund UniversityLundSweden
| | - Pontus Tideman
- Clinical Memory Research Unit, Department of Clinical Sciences MalmöLund UniversityLundSweden
- Memory ClinicSkåne University HospitalMalmöSweden
| | - Emrah Düzel
- German Center for Neurodegenerative DiseasesMagdeburgGermany
- Institute for Cognitive Neurology and Dementia ResearchOtto‐von‐Guericke UniversityMagdeburgGermany
- Institute of Cognitive NeuroscienceUniversity College LondonLondonUK
| | - Sebastian Palmqvist
- Clinical Memory Research Unit, Department of Clinical Sciences MalmöLund UniversityLundSweden
- Memory ClinicSkåne University HospitalMalmöSweden
| | - Erik Stomrud
- Clinical Memory Research Unit, Department of Clinical Sciences MalmöLund UniversityLundSweden
- Memory ClinicSkåne University HospitalMalmöSweden
| | - Oskar Hansson
- Clinical Memory Research Unit, Department of Clinical Sciences MalmöLund UniversityLundSweden
- Memory ClinicSkåne University HospitalMalmöSweden
| |
Collapse
|
4
|
Gu X, Qi L, Qi Q, Zhou J, Chen S, Wang L. Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets. Biosci Trends 2024; 18:49-65. [PMID: 38382942 DOI: 10.5582/bst.2023.01288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2024]
Abstract
Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. Due to the complexity of the disorder and the presence of the blood-brain barrier (BBB), its drug discovery and development are facing enormous challenges, especially after several failures of monoclonal antibody (mAb) trials. Nevertheless, the Food and Drug Administration's approval of the mAb aducanumab has ushered in a new day. As we better understand the disease's pathogenesis and identify novel intracerebral therapeutic targets, antibody-based therapies have advanced over the past few years. The mAb drugs targeting β-amyloid or hyperphosphorylated tau protein are the focus of the current research. Massive neuronal loss and glial cell-mediated inflammation are also the vital pathological hallmarks of AD, signaling a new direction for research on mAb drugs. We have elucidated the mechanisms by which AD-specific mAbs cross the BBB to bind to targets. In order to investigate therapeutic approaches to treat AD, this review focuses on the promising mAbs targeting intracerebral dysfunction and related strategies to cross the BBB.
Collapse
Affiliation(s)
- Xiaolei Gu
- College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, Hubei, China
| | - Long Qi
- New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, China
| | - Qing Qi
- Laboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
- The Academy of Integrative Medicine of Fudan University, Shanghai, China
- Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China
| | - Jing Zhou
- Laboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
- The Academy of Integrative Medicine of Fudan University, Shanghai, China
- Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China
| | - Song Chen
- Postdoctoral Station of Xiamen University, Fujian, China
| | - Ling Wang
- Laboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
- The Academy of Integrative Medicine of Fudan University, Shanghai, China
- Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China
| |
Collapse
|
5
|
Pajewski NM, Donohue MC, Raman R, Espeland MA. Ascertainment and Statistical Issues for Randomized Trials of Cardiovascular Interventions for Cognitive Impairment and Dementia. Hypertension 2024; 81:45-53. [PMID: 37732473 PMCID: PMC10840823 DOI: 10.1161/hypertensionaha.123.19941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/22/2023]
Abstract
There has been considerable progress in the prevention and treatment of cardiovascular disease, reducing the population burden of cardiovascular morbidity and mortality. Recently, some randomized trials, including the SPRINT (Systolic Blood Pressure Intervention Trial), have suggested that improvements in cardiovascular risk factors may also slow cognitive decline and reduce the eventual development of dementia. Unfortunately, the randomized trial template that has been used repeatedly to successfully demonstrate reductions in major adverse cardiac events faces several design and analytic obstacles when applied in the context of cognitive decline and dementia. Here, we review these obstacles, motivated by SPRINT and the context of selecting an appropriate cognitive end point for future preventive randomized trials. A few options are available, spanning neuropsychological test scores or composites reflecting specific domains of cognitive function, adjudicated cognitive impairment, or potentially physiological biomarkers. This choice entails considerations around statistical power, modes of ascertainment, the clinical relevance of treatment effects, a myriad of statistical issues (interval censoring, missing data, the competing risk of death, practice effects, etc), as well as ethical considerations around equipoise. Collectively, these considerations indicate that trials aiming to mitigate the cardiovascular contribution to cognitive decline and dementia will generally need to be large, inclusive of a wide age range of older adults, and with multiple years of follow-up.
Collapse
Affiliation(s)
- Nicholas M. Pajewski
- Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC
| | - Michael C. Donohue
- Alzheimer’s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA
| | - Rema Raman
- Alzheimer’s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA
| | - Mark A. Espeland
- Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC
- Section of Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
| |
Collapse
|
6
|
Huang S, Wen X, Liu Z, Li C, He Y, Liang J, Huang W. Distinguishing functional and structural MRI abnormalities between bipolar and unipolar depression. Front Psychiatry 2023; 14:1343195. [PMID: 38169701 PMCID: PMC10758430 DOI: 10.3389/fpsyt.2023.1343195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2023] [Accepted: 12/05/2023] [Indexed: 01/05/2024] Open
Abstract
Background This study aims to investigate the underlying characteristics of spontaneous brain activity by analyzing the volumes of the hippocampus and parahippocampal gyrus, as well as the fractional amplitude of low-frequency fluctuation (fALFF) and regional homogeneity (ReHo), in order to differentiate between bipolar disorder (BD) and unipolar depressive disorder. Methods A total of 46 healthy controls, 58 patients with major depressive disorder (MDD), and 61 patients with BD participated in the study and underwent resting-state functional magnetic resonance imaging (rs-fMRI) scans. The researchers calculated the differences in volume, fALFF, and ReHo values among the three groups. Additionally, they conducted correlation analyses to examine the relationships between clinical variables and the aforementioned brain measures. Results The results showed that the BD group exhibited increased fALFF in the hippocampus compared to the healthy control (HC) and MDD groups. Furthermore, the ReHo values in the hippocampus and parahippocampal gyrus were significantly higher in the BD group compared to the HC group. The findings from the person correlation analysis indicated a positive relationship between ReHo values in the hippocampus and both HAMD and HAMA scores. Moreover, there was no correlation between the volumes, fALFF, and ReHo values in the hippocampus and parahippocampal gyrus, and cognitive function levels (RBANS). Conclusion Taken together, these aberrant patterns of intrinsic brain activity in the hippocampus and parahippocampal gyrus may serve as quantitative indicators for distinguishing between BD and unipolar depression.
Collapse
Affiliation(s)
| | | | | | | | | | - Jiaquan Liang
- Department of Psychiatry, The Third People’s Hospital of Foshan, Foshan, Guangdong, China
| | - Wei Huang
- Department of Psychiatry, The Third People’s Hospital of Foshan, Foshan, Guangdong, China
| |
Collapse
|